E N D
1. NEW CHALLENGESIN KIDNEY CANCERBEVACIZUMAB Pr Alain Ravaud. Medical Oncology. University Hospital- Bordeaux- France
2. BEVACIZUMAB Humanized VEGF mAb
93% human
Dose :
3mg/kg : Pk similar to optimally effective dose in preclinical mouse model
10 mg/kg max.dose in phase I with no MTD
4. BEVACIZUMAB. > 1st LINE
6. BEVACIZUMAB
7. BEVACIZUMAB 1st targeted drug validating a modification of the natural history of MRCC
Validation of angiogenesis as a major event in MRCC natural history as least by the VEGF pathway
Manageable safety profile
? go to 1st line
? Explore combination for VEGF or other pathway
8. BEVACIZUMAB. 1ST LINE
9. BEVACIZUMAB. 1ST LINE
10. BEVACIZUMAB. 1ST LINE
11. BEVACIZUMAB. 1ST LINE
13. AVOREN
A randomized,
double-blind, placebo-controlled phase III study
to evaluate the efficacy and safety of bevacizumab in combination with interferon alfa-2a
versus interferon alfa-2a and placebo
as first-line treatment administered
to patients
with MRCC
18. PFS AND MOTZER’S RISK GROUP
22. BEVACIZUMAB + OTHERS Bevacizumab + anti VEGF pathway
+ Sunitinib : phase I ? II
+ Sorafenib : phase I ? II
Bevacizumab + mTOR inhition
+ CCI : phase I
+ RAD 001 : phase I
23. BEVACIZUMAB Highly effective in MRCC
Effective as 1st line or following immunotherapy
Low level of complete response
Unknown : Bevacizumab + INF or Bevacizumab alone ?
New option in 1st line in MRCC with Sunitinib as the standard